ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Supplemental New Drug Applications to Include New Data in Product Labels for Synjardy®,
January 06, 2017The U.S. Food and Drug Administration has approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark EMPA-REG OUTCOME® trial. -
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for
January 06, 2017The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark EMPA-REG OUTCOME® trial.
Pharma Sources Insight January 2025
